# A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

> **NCT00496132** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** PRO131921

## Key facts

- **NCT ID:** NCT00496132
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08-27
- **Primary completion:** 2009-06-17
- **Final completion:** 2009-06-17
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496132, "A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00496132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*